Munich’s MorphoSys and I-MAB Biopharma sign agreement on MOR202 therapeutic antibody against multiple myeloma and other diseases

I-MAB, a Shanghai-based startup has agreed with MorphoSys on the exclusive development and commercialization of MOR202 in China, Taiwan, Hong Kong and Macau. The investigational drug MOR202 is a human HuCAL antibody directed against the CD38 target. Scientifically proven, CD38 is a highly expressed target protein in multiple myeloma. In addition to the treatment of multiple myeloma, studies have found that CD38 antibodies have a therapeutic effect on a variety of solid tumors and autoimmune diseases. MorphoSys is completing Phase 1 / 2a clinical studies of MOR202 in Germany and Austria.

China Bio news release, December 2, 2017

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny